Kouroukis, C Tom <br/><br/>
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).  [electronic resource] 

 -  Leukemia & lymphoma  Mar 2011 
 - 394-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2010.546015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Canada<br/>Clinical Trials as Topic<br/>Deoxycytidine--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Male<br/>Medical Oncology--organization & administration<br/>Middle Aged<br/>National Health Programs<br/>Pyrazines--administration & dosage<br/>Recurrence<br/>Societies, Medical<br/>Gemcitabine